Template:Second-generation BTKi table: Difference between revisions

From Embryology
mNo edit summary
mNo edit summary
Line 2: Line 2:
|+ '''Novel Bruton’s Tyrosine Kinase (BTK) Inhibitors for CCL Treatment'''
|+ '''Novel Bruton’s Tyrosine Kinase (BTK) Inhibitors for CCL Treatment'''
|-bgcolor="CEDFF2"
|-bgcolor="CEDFF2"
! width=120px|BTK inhibitor
! width=110px|BTK inhibitor
! width=150px|BTK binding mechanism
! width=150px|BTK binding mechanism
! width=80px|Selectivity for BTK
! width=80px|Selectivity for BTK
! width=220px|Relevant non-BTK targets
! width=240px|Relevant non-BTK targets
! width=120px|Phase of clinical development
! width=100px|Phase of clinical development
|-
|-
| Acalabrutinib  
| Acalabrutinib  

Revision as of 14:08, 30 April 2019

Novel Bruton’s Tyrosine Kinase (BTK) Inhibitors for CCL Treatment
BTK inhibitor BTK binding mechanism Selectivity for BTK Relevant non-BTK targets Phase of clinical development
Acalabrutinib Covalent, irreversible High N/A II/III
Zanubrutinib Covalent, irreversible Moderate N/A II/III
Tirabrutinib Covalent, irreversible High N/A I/II
Vecabrutinib Non-covalent, reversible Moderate interleukin-2-inducible (ITK) I/II
LOXO-305 Non-covalent, reversible High N/A I
ARQ-531 Non-covalent, reversible Low Lck/Yes novel tyrosine kinase (LYN),
mitogen-activated protein kinase kinase 1 (MEK1)
I
Table data [1]
  1. Bond DA & Woyach JA. (2019). Targeting BTK in CLL: Beyond Ibrutinib. Curr Hematol Malig Rep , , . PMID: 31028669 DOI.